Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mukhopadhyay, C. K.
Right arrow Articles by Fox, P. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mukhopadhyay, C. K.
Right arrow Articles by Fox, P. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Volume 271, Number 25, Issue of June 21, 1996 pp. 14773-14778
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Ceruloplasmin Enhances Smooth Muscle Cell- and Endothelial Cell-mediated Low Density Lipoprotein Oxidation by a Superoxide-dependent Mechanism*

(Received for publication, October 17, 1995, and in revised form, January 31, 1996)

Chinmay K. Mukhopadhyay , Eduardo Ehrenwald and Paul L. Fox Dagger

From the Department of Cell Biology, Cleveland Clinic Research Institute, Cleveland, Ohio 44195

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

Cultured vascular smooth muscle cells (SMC) and endothelial cells (EC) stimulate low density lipoprotein (LDL) oxidation by free radical-mediated, transition metal-dependent mechanisms. The physiological source(s) of metal ions is not known; however, purified ceruloplasmin, a plasma protein containing 7 coppers, oxidizes LDL in vitro. We now show that ceruloplasmin also increases LDL oxidation by vascular cells. In metal ion-free medium, human ceruloplasmin increased bovine aortic SMC- and EC-mediated LDL oxidation by up to 30- and 15-fold, respectively. The maximal response was at 100-300 µg ceruloplasmin/ml, a level at or below the unevoked physiological plasma concentration. Oxidant activity was dependent on protein structure as a specific proteolytic cleavage or removal of one of the seven ceruloplasmin copper atoms inhibited activity. Three lines of evidence indicated a critical role for cellular superoxide (Obardot 2) in ceruloplasmin-stimulated oxidation. First, the rate of production of Obardot 2 by cells correlated with their rates of LDL oxidation. Second, superoxide dismutase effectively blocked ceruloplasmin-stimulated oxidation by both cell types. Finally, Obardot 2 production by SMC quantitatively accounted for the observed rate of LDL oxidation. To show this, the course of Obardot 2 production by SMC was simulated by repeated addition of xanthine and xanthine oxidase to culture medium under cell-free conditions. Neither ceruloplasmin nor Obardot 2 alone increased LDL oxidation, but together they completely reconstituted the oxidation rate of ceruloplasmin-stimulated SMC. These results are the first to show that ceruloplasmin stimulates EC- and SMC-mediated oxidation of LDL and that cell-derived Obardot 2 accounts quantitatively for metal-dependent, free radical-initiated oxidation of LDL by these cells.


INTRODUCTION

Oxidative modification of low density lipoprotein (LDL)1 by incubation with iron or copper salts generates a particle with altered chemical properties including elevated levels of lysophosphatidylcholine and oxidized lipids and increased electrophoretic mobility (1). Besides inducing foam cell formation in cultured macrophages (2), oxidized LDL has other properties in vitro consistent with a pro-atherogenic function, e.g., it increases macrophage residence in the vessel wall by chemoattractant activity for monocytes (3), by inducing cellular production of chemoattractants (4), and by enhancing monocyte binding to EC (Ref. 5; see Ref. 6 for review). Oxidized LDL also is chemotactic for SMC (7) and reduces EC wound-healing responses (8) in vitro.

Although the presence of oxidized LDL in atherosclerotic lesions has been established (9, 10), the mechanism(s) of oxidation in vivo is unknown. LDL may be oxidized in the plasma and taken up by the vessel wall, or it may be oxidized within the vessel wall by cell-mediated processes. Oxidation of LDL by cells of the type found in the vessel wall, including EC (11, 12), SMC (11, 13), and monocytic cells (14, 15, 16) has been described. Cell-derived superoxide (Obardot 2) is required for oxidation of LDL by SMC (17), EC (18), and adherent monocytic cells (16, 19), although conflicting results have been reported for the latter two cell types (20, 21). LDL oxidation by EC (12) and SMC (13) also requires exogenous transition metal ions.

Given the absence of measurable free copper and iron in plasma and interstitial fluids (22), recent attention has focused on the identification of physiological metal-containing complexes that promote LDL oxidation (23, 24, 25) and on metal ion-independent mechanisms of oxidation (26, 27). We (28, 29) and others (30, 31) have investigated the role of the copper-containing plasma protein ceruloplasmin in this process. Ceruloplasmin is an acute phase reactant containing 7 copper atoms and carrying about 95% of plasma copper (see Refs. 32 and 33 for review). Ceruloplasmin has a well documented ``oxidase'' activity capable of oxidizing aromatic amines and ferrous ions (32). This activity is thought to be catalyzed by a 4-copper complex within ceruloplasmin and accompanied by 4-electron reduction of O2 to H2O (34).

In addition to its oxidase activity, purified human ceruloplasmin oxidatively modifies LDL as measured by multiple determinants of lipid oxidation including formation of thiobarbituric acid reacting-substances (TBARS), conjugated dienes, and lipid hydroperoxides and by increased electrophoretic mobility (29). The oxidant activity of ceruloplasmin is strongly dependent on protein structure; incubation with Chelex-100 (which removes only one of seven copper atoms) and proteolytic cleavage at a single site (into 115- and 19-kDa fragments) both suppress activity (29). We now present evidence that intact human ceruloplasmin stimulates oxidative modification of LDL by vascular cells and that this activity depends on the cellular release of Obardot 2.


EXPERIMENTAL PROCEDURES

Materials

Ceruloplasmin was purified from human plasma as described (28). The resulting ceruloplasmin preparation was pure as determined by oxidase specific activity (35), by an absorbance ratio (610 nm/280 nm) greater than 0.045 (32), and by homogeneity according to SDS-polyacrylamide gel electrophoresis and silver staining. Purified ceruloplasmin was primarily the intact 132-kDa monomer but also contained the 115- and 19-kDa proteolytic fragments of ceruloplasmin also present in serum (about 10% of total by SDS-polyacrylamide gel electrophoresis). Catalase, dimethylthiourea, glutathione, sodium formate, superoxide dismutase, xanthine, xanthine oxidase, and all assay reagents were from Sigma, and Chelex-100 was from Bio-Rad.

Cell Culture

EC were isolated from adult bovine aortas as described (36), subcultured by trypsinization, and grown to confluence in Dulbecco's modified Eagle's medium and Ham's F-12 medium containing 5% fetal calf serum (Hyclone Laboratories, Logan, UT). SMC were isolated by the explant method using intima-media of adult bovine aortas (37). The cells were made quiescent in Dulbecco's modified Eagle's medium containing 1 mg/ml gelatin for at least 24 h. SMC proliferation was measured as incorporation of [3H]thymidine into trichloroacetic acid-precipitable material (36), the rate of protein synthesis by SMC was measured as incorporation of [3H]leucine into trichloroacetic acid-precipitable material, and EC migration was measured by the razor-wound assay as described previously (8). Human aortic EC cultured on a fibronectin-coated (1 µg/cm2) surface, and human aortic SMC were used in some experiments.

Lipoprotein Methods

Human LDL (density = 1.019-1.063 g/ml) was prepared by sequential ultracentrifugation from freshly drawn, citrated plasma to which EDTA was added before centrifugation (38). Before use, LDL was dialyzed at 4 °C against saline and incubated with cell cultures in serum- and transition metal-free RPMI 1640 medium at 37 °C. LDL oxidation was determined as TBARS in the conditioned medium and expressed as nmol malondialdehyde-equivalents/mg LDL cholesterol. LDL oxidation was also measured as the formation of conjugated dienes (39), total lipid peroxide content (40), and conversion of phosphatidylcholine to lysophosphatidylcholine by solvent extraction, thin layer chromatography, and Coomassie Blue staining (41). Lipoprotein-deficient serum (LPDS; density > 1.25) was prepared by ultracentrifugation of human plasma (38).

Other Methods

Superoxide production by cells (or by a xanthine/xanthine oxidase generating system) was measured spectrophotometrically by Cu/Zn-superoxide dismutase (SOD)-inhibited reduction of cytochrome c (42). Cultured cells were incubated in RPMI 1640 medium (without phenol red dye) with 3 × 10-5 M cytochrome c. Obardot 2-specific reduction of cytochrome c was determined as the difference in absorbance at 550 nm between dishes incubated ± SOD (100 units/ml). Cell-free dishes were used as controls.


RESULTS

Effect of Human Ceruloplasmin on SMC- and EC-mediated LDL Oxidation

The ability of human ceruloplasmin to promote LDL oxidation by bovine aortic SMC and EC was investigated. LDL and purified human ceruloplasmin were added to confluent cell cultures in serum- and transition metal-free RPMI 1640 medium. Ceruloplasmin stimulated SMC-mediated oxidation, measured as TBARS, from less than 1 to about 30 nmol malondialdehyde/mg cholesterol (Fig. 1A). The activation curve was sigmoidal with half-maximal activity at 25-50 µg/ml and maximal oxidation at 100 µg/ml, a concentration below the mean unevoked plasma concentration of 300 µg/ml. Ceruloplasmin at concentrations up to 300 µg/ml did not alter the cellular rate of protein synthesis as measured by [3H]leucine uptake. Ceruloplasmin-stimulated oxidation of LDL was confirmed by three other chemical measures of LDL oxidation. In the presence of SMC, a maximal amount of ceruloplasmin increased: (i) the level of conjugated dienes in LDL from 0.04 to 0.12 absorbance units (A234 nm), (ii) the amount of lipid peroxides from 0.0 to 0.7 µmol/mg LDL cholesterol, and (iii) the lysophosphatidylcholine content of LDL from 10 ± 8 to 260 ± 20 µg of lysophosphatidylcholine/mg LDL cholesterol (not shown). Furthermore, LDL oxidized by the combined presence of ceruloplasmin and bovine SMC had two biological activities that have been described for metal ion-oxidized LDL (8, 43); it stimulated SMC proliferation (measured by [3H]thymidine uptake) by about 75%, and almost completely inhibited EC migration (measured by the razor-wound assay (8)) with a half-maximal inhibition at 100 µg LDL cholesterol/ml (not shown). Ceruloplasmin also stimulated LDL oxidation by bovine aortic EC but to a lesser extent than by SMC (Fig. 1A). In multiple independent experiments, the maximal ceruloplasmin-stimulated oxidant activity of EC was 15-50% of that of SMC. Similar enhancement of oxidation by ceruloplasmin was seen with aortic SMC and EC derived from adult human tissue; the maximal oxidation (at 100 µg/ml of ceruloplasmin) by human SMC was 18-22 nmol malondialdehyde/mg cholesterol, and stimulation by human EC was generally 50-75% of that of SMC (not shown).


Fig. 1. Stimulation of cell-mediated LDL oxidation by intact ceruloplasmin. A, bovine aortic SMC (bullet ), EC (square ), or cell-free wells (open circle ) were incubated with LDL and ceruloplasmin for 24 h in RPMI 1640 medium. Lipoprotein oxidation was determined as TBARS. B, SMC were incubated with LDL in the presence (black-square) or the absence (square ) of 100 µg of ceruloplasmin. Similarly, EC cultures were incubated with LDL in the presence (bullet ) or the absence (open circle ) of ceruloplasmin. LDL incubated with ceruloplasmin in cell-free wells served as controls (×). C, SMC were incubated for 24 h with LDL and 100 µg/ml (square ) or 500 µg/ml (black-square) of ceruloplasmin in the presence of up to 10% LPDS. D, purified human ceruloplasmin was proteolytically modified by incubation with partially purified metalloproteinase isolated during ceruloplasmin purification (28, 29). After 22 h at 37 °C in 25 mM Tris-HCl, 10 mM CaCl2, pH 6.6, ceruloplasmin was completely modified to 115- and 19-kDa fragments (by silver-stained SDS-polyacrylamide gel electrophoresis gels, not shown). Ceruloplasmin was also incubated with Chelex-100 beads for 4 h at 23 °C, and the supernatant taken after centrifugation. LDL was incubated for 20 h at 37 °C with intact (bullet ), protease-treated (×), or Chelex 100-treated (triangle ) ceruloplasmin.

A time course experiment using aortic SMC showed a 2-3-h lag followed by a nearly linear increase in ceruloplasmin-stimulated oxidation of LDL for at least 24 h (Fig. 1B). The lag before the appearance of detectable amounts of TBARS in EC was longer, about 10 h, and the rate of oxidation during the linear phase was less than half of that seen with SMC. The longer lag phase in EC may be due to its lower rate of production of reactive oxygen intermediates (see below), and consequently slower destruction of the antioxidants within LDL believed to be responsible for the observed lag period (39). Ceruloplasmin by itself, i.e., in the absence of cells, only slightly increased LDL oxidation (Fig. 1, A and B). This observation was consistent with our earlier results showing that ceruloplasmin oxidized LDL in phosphate-buffered saline but that proteins and amino acids blocked its activity (29). The ability of cultured cells to overcome the inhibition by amino acids in the culture medium indicated that SMC and EC cells may supply an additional factor(s) required for ceruloplasmin-stimulated LDL oxidation under these conditions. The well known nonspecific antioxidant activity of proteins (44, 45) raises questions on the physiological relevance of the stimulation of cellular oxidation of LDL by ceruloplasmin. However, LPDS (used instead of serum to minimize the complicating presence of lipoproteins), at concentrations as high as 10%, inhibited the oxidant activity of 100 µg/ml ceruloplasmin by only 30%, and no inhibition of 500 µg/ml ceruloplasmin was observed (Fig. 1C).

Treatment of ceruloplasmin with Chelex-100 removes one of seven copper atoms and suppresses oxidant activity under cell-free conditions (29). The results in Fig. 1D showed that pre-treatment of ceruloplasmin with Chelex-100 totally blocked its ability to support SMC-mediated (and EC-mediated, not shown) LDL oxidation. Ceruloplasmin was subjected to proteolytic modification by incubation with a partially purified preparation of the metalloproteinase separated from ceruloplasmin during its purification (28). The treatment modified the intact 132-kDa ceruloplasmin molecule to a complex of 115- and 19-kDa degradation fragments. Proteolytically modified ceruloplasmin did not stimulate SMC-mediated (and EC-mediated, not shown) LDL oxidation (Fig. 1D).

Role of Superoxide in Ceruloplasmin-stimulated LDL Oxidation by Cells

Several laboratories have shown evidence that cellular release of Obardot 2 is required for metal ion-dependent, EC- and SMC-mediated LDL oxidation (18, 42). In those studies transition metals were supplied either as free iron or copper in the culture medium. We therefore examined the role of Obardot 2 in ceruloplasmin-stimulated cell oxidation processes. The rate of Obardot 2 production by confluent bovine EC and SMC cultures was measured at 15 min intervals by spectrophotometric measurement of superoxide dismutase-inhibited reduction of cytochrome c. The generation rate by SMC cultures was linear for 60 min with a production rate of 2.30 nmol/well/h. This rate was 85% higher than that by EC, which had a rate of 1.25 nmol/well/h. The level of LDL oxidation (measured as TBARS) by SMC was about 105% higher than that by EC providing correlative evidence for a relationship between Obardot 2 production and LDL oxidation by these cell types. A similar relationship was seen for human aortic EC and SMC (not shown) and has been described in multiple isolates of monkey SMC (42).

To further address the role of Obardot 2 production in ceruloplasmin- and cell-mediated oxidation, inhibition by scavengers of Obardot 2 and other reactive oxygen species was examined. Cu/Zn-SOD blocked about 80% of ceruloplasmin-stimulated oxidation by SMC cultures (Fig. 2A). Because dismutation of Obardot 2 releases H2O2, we also added catalase to eliminate the latter species. Although catalase alone was not an effective inhibitor, SOD and catalase in combination blocked all LDL oxidation. Essentially identical results were seen in human aortic SMC and in human and bovine aortic EC (not shown). Heat treatment completely inactivated SOD (as shown by measuring Obardot 2 production by the xanthine/xanthine oxidase system), and the inactivated enzyme did not reduce ceruloplasmin-stimulated oxidation by SMC, even in the presence of catalase. Jessup et al. (21) have suggested that heat inactivation of SOD may release free metal ions that exert oxidant activity and thereby mask antioxidant activity. To test this possibility, heat-inactivated SOD was subsequently treated with Chelex-100 to remove free divalent metal ions and was found to give the same results as heat-inactivated SOD. Three hydroxyl radical scavengers, mannitol, glutathione, and sodium formate, did not significantly reduce ceruloplasmin-stimulated LDL oxidation by SMC. However, dimethylthiourea, also a hydroxyl radical scavenger, was effective. At least two possibilities are consistent with these data: (i) hydroxyl radical is required for LDL oxidation under these conditions, but only dimethylthiourea has sufficient scavenging activity, or (ii) hydroxyl radical is not required for oxidation, and dimethylthiourea exerts its inhibitory activity by a distinct pathway. The second scenario is supported by the observation that dimethylthiourea covalently interacts with Obardot 2 (46). We confirmed that dimethylthiourea blocked Obardot 2 production by xanthine and xanthine oxidase (not shown).


Fig. 2. Effect of free radical inhibitors on ceruloplasmin-stimulated, cell-mediated LDL oxidation. A, SMC were incubated with LDL (widely striped bar), LDL plus 100 µg/ml of ceruloplasmin (black bar), and LDL plus ceruloplasmin and inhibitors of lipid oxidation (densely striped bars) for 24 h. The inhibitors used were Cu, Zn-SOD (100 units/ml), catalase (1000 units/ml), mannitol (20 mM), glutathione (reduced, 50 mM), sodium formate (100 mM), and dimethylthiourea (10 mM). SOD was heated at 95 °C for 10 min (SOD (heated)), and activity loss was shown using a Obardot 2-generating system containing xanthine and xanthine oxidase. B, in a time course experiment SMC were incubated with LDL and 100 µg/ml ceruloplasmin, and either 100 units/ml SOD (square ) or SOD plus 1000 units/ml catalase (open circle ) added at the time indicated. In control wells, SMC were incubated with LDL in the absence of ceruloplasmin (shaded circle and shaded square) or with ceruloplasmin (Cp) but in the absence of any inhibitor (bullet ,black-square).

Obardot 2 may be necessary for initiating lipid peroxidation, in which case it may be needed only during the beginning of the reaction period; alternatively, Obardot 2 may be necessary for subsequent propagation reactions, which may require its continuous presence. To examine the temporal requirement for Obardot 2, SOD or SOD plus catalase were added to bovine aortic SMC after initiation of oxidation by the addition of ceruloplasmin (Fig. 2B). After an incubation interval totaling 24 h, ceruloplasmin-stimulated LDL oxidation was measured. SOD was found to block subsequent LDL oxidation, independent of its time of addition. This result shows that the early presence of Obardot 2 is not sufficient to initiate oxidation at maximal levels, but rather that the continuous generation of Obardot 2 is required.

Reconstitution of SMC Oxidant Activity by Ceruloplasmin and Superoxide

A cell-free reconstitution strategy was used to determine if the cell contribution of Obardot 2 can account quantitatively for cellular oxidation of LDL by SMC in the presence of ceruloplasmin. Xanthine and xanthine oxidase were used under aerobic conditions to generate Obardot 2. In this system, xanthine is oxidized to urate by xanthine oxidase with consequent reduction of O2 to Obardot 2. We first developed an appropriate protocol that mimicked the cellular environment. Concentrations of xanthine and xanthine oxidase were chosen such that the rate of release of Obardot 2 closely approximated that by cultured SMC (about 6 nmol in 3 h). Under these conditions, the rate of Obardot 2 production by the generating system was nearly constant for up to 2-3 h and then gradually dropped off, presumably due to enzyme inactivation under these conditions. The rate of Obardot 2 production by cultured SMC was constant for at least 24 h. A single addition of xanthine/xanthine oxidase to SMC in the presence of ceruloplasmin increased LDL oxidation during a 24-h interval almost 3-fold, a stimulation much less than the 9-fold increase by ceruloplasmin-treated SMC (Fig. 3A). When the Obardot 2 generating system was repeatedly added at 3-h intervals for 24 h, LDL oxidation was increased about 8-fold to an extent closely approximating SMC-mediated oxidation. This amount of Obardot 2 (given according to the same regimen) was completely inactive in the absence of ceruloplasmin. Application of a large ``burst'' of Obardot 2 (by a single addition of the same amount of xanthine and xanthine oxidase used in the multiple addition regimen) did not increase LDL oxidation beyond that found with the single small dose. Thus early addition of Obardot 2, even at high levels, is not sufficient to induce maximal, long-term oxidation (confirming the results of Fig. 2B). More importantly, the results show quantitatively that the amount of Obardot 2 produced by SMC is sufficient to account for the observed ceruloplasmin-dependent oxidation by the cells.


Fig. 3. Reconstitution of SMC-mediated LDL oxidation by ceruloplasmin and superoxide and the role of stable SMC products. A, LDL was incubated for 24 h (lane 1) under cell-free conditions (widely striped bars). Obardot 2 was generated under the same conditions by the addition of 1 mM xanthine and 0.15 mM xanthine oxidase at the start of the incubation (lanes 2 and 5). This xanthine/xanthine oxidase (X/XO) system was found to approximate the rate of Obardot 2 release by SMC (about 6 nmol in 3 h). To simulate continuous release of Obardot 2 by SMC, 0.15 milliunit of xanthine oxidase was resupplied at 3-h intervals (lanes 3 and 6). An initial burst of 45-50 nmol of Obardot 2 (during a 30-min interval) was generated by the addition of 0.1 mM xanthine and 1 milliunit of xanthine oxidase (lane 7). Ceruloplasmin (100 µg/ml) was added to the cell-free incubation tubes (lanes 4-7) and also to cultured SMC (lane 8, densely striped bar). A schematic representing the time course of Obardot 2 generation is shown at top. B, SMC were allowed to condition RPMI 1640 medium for 24 h. The conditioned medium was subsequently incubated for 24 h with LDL (lane 1) under cell-free conditions (widely striped bars). To LDL-containing conditioned medium was added 100 µg/ml of ceruloplasmin (Cp, lanes 2, 4, 5, and 6). In some wells 1 mM xanthine and 0.15 milliunit of xanthine oxidase were added repeatedly as in A to simulate Obardot 2 generation by SMC (lanes 3-6). SOD (lane 5, 100 units/ml) and catalase (lane 6, 1000 U/ml) were also added. Wells containing SMC (densely striped bars) were incubated for 24 h in the absence (lane 7) or the presence (lane 8) of ceruloplasmin.

Although these studies show the continuous requirement for the short-lived Obardot 2 species, we also investigated the role of long-lived cellular products on LDL oxidation. Conditioned medium taken from SMC after a 24-h incubation did not cause significant oxidation of LDL either by itself or in the presence of ceruloplasmin, indicating that stable cell products do not contribute significantly to cell-mediated oxidation by ceruloplasmin (Fig. 3B). Likewise, the addition of xanthine and xanthine oxidase to conditioned medium did not enhance LDL oxidation. Simultaneous addition of ceruloplasmin and the Obardot 2 generating system (added at 3-h intervals) to SMC-conditioned medium resulted in oxidation to nearly the same extent as that induced by ceruloplasmin in the presence of SMC cultures. Thus inhibitory agents are not present in SMC-conditioned medium, and oxidant activity of SMC is effectively reconstituted by ceruloplasmin and Obardot 2 under conditions very similar to those present in cultured cells.


DISCUSSION

Lipoprotein oxidation occurs by both metal ion-dependent and -independent pathways in vitro (47). Given the virtual absence of free copper and iron in plasma and other biological fluids (22), the elucidation of protein-bound metal ions that catalyze LDL oxidation represents an important goal in understanding mechanisms of metal ion-dependent oxidation processes in vivo. Our results indicate that human ceruloplasmin at subphysiological concentrations can substitute for free metal ions in stimulating LDL oxidation by vascular cells. Ceruloplasmin copper is required for the activity because pretreatment with Chelex-100 is completely inhibitory. The treatment removes only one of the seven ceruloplasmin copper atoms (29), indicating that this specific copper is required for cell-mediated oxidation. Because treatment with Chelex-100 does not diminish ceruloplasmin amine oxidase activity (29), these results also indicate that oxidase activity is not sufficient to induce cell-mediated LDL oxidation. Cleavage of ceruloplasmin into 115- and 19-kDa fragments completely inactivates the protein. The requirement for intact protein may explain the reported inability of ceruloplasmin to stimulate LDL oxidation by monocytic cells unless ceruloplasmin was pretreated with acid (and copper released, presumably by denaturation) (30). Because about 10% of the ceruloplasmin in plasma is present as the proteolytically modified isoform, it is tempting to speculate that proteolysis represents a physiological mechanism regulating oxidant activity.

Under the conditions of these experiments, ceruloplasmin did not significantly oxidize LDL in the absence of cells. This result contrasts with previous results showing that ceruloplasmin by itself is sufficient to oxidize LDL (when co-incubated in phosphate-buffered saline) (29). This apparent discrepancy is explained by our previous results that show that several proteins and also a mixture of amino acids inhibit ceruloplasmin oxidant activity (29). Thus the inhibition of LDL oxidation by the amino acids in RPMI 1640 (and perhaps other medium components) is consistent with our previous observations using ceruloplasmin and with observations by others using free metal ion systems (44, 48). Because oxidation does occur in the presence of either SMC or EC, these results also suggest that a critical factor(s) provided by the cells is essential for ceruloplasmin-stimulated LDL oxidation under these conditions. The high rate of LDL oxidation in the presence of 10% LPDS contrasts with a recent observation that 6% serum blocked almost 90% of the oxidation induced by murine macrophages in the presence of 10 µM iron complexed to nitriloacetic acid (45). We have not yet resolved whether the different results are due to higher oxidant activity of ceruloplasmin compared with the iron complex, higher activity of EC and SMC compared with murine macrophages, or lower antioxidant activity of LPDS compared with heat-inactivated serum. That ceruloplasmin-stimulated oxidation occurs in the presence of 10% LPDS (and a fibronectin matrix for human EC) suggests that this process may also occur under physiological conditions.

Three experimental avenues indicate that cell-derived Obardot 2 is a critical factor necessary for ceruloplasmin-stimulated LDL oxidation by vascular cells. First, the rate of production of Obardot 2 by SMC was twice that of EC, consistent with their differential rates of LDL oxidation. This result agrees with previous results showing that cells that oxidize LDL also secrete Obardot 2 and that the rate of Obardot 2 production by a particular cell isolate correlates with its ability to oxidize LDL (18, 42). Second, the addition of SOD effectively blocked ceruloplasmin-stimulated LDL oxidation by both SMC and EC. This result is also consistent with published reports of inhibition of cell-mediated LDL oxidation by SOD or by inhibition of Obardot 2 production by elimination of L-cystine from the medium (49). We now add a third line of evidence in support of the role of Obardot 2 in cell-mediated oxidation, namely, that the measured rate of Obardot 2 production by cells can quantitatively account for the level of oxidation observed (in the presence of ceruloplasmin). Repeated addition of xanthine and xanthine oxidase to simulate continuous Obardot 2 production by SMC in the presence of ceruloplasmin and LDL completely reconstituted the oxidation rate of SMC.

Although our results clearly indicate a role for Obardot 2 in ceruloplasmin-stimulated oxidation by EC and SMC, its reported role in free metal ion-stimulated cell oxidation processes is controversial (see Ref. 50 for review). The role of Obardot 2 in SMC oxidation of LDL has not been extensively investigated, but Heinecke et al. (42) have shown that LDL oxidation is inhibited by SOD and that a correlation exists between Obardot 2 production and LDL oxidation by several isolates of monkey SMC. The role played by Obardot 2 in EC oxidation of LDL is not clear because oxidation has been reported to be not inhibited (51), slightly inhibited (20), and completely inhibited (18) by SOD. The role of Obardot 2 in monocytic cell oxidation of LDL is also controversial (16, 19, 21). One limitation of most of these studies is the dependence on a single approach, i.e., inactivation of Obardot 2 by SOD. Thus the reported discrepancies may be due to variable activities of SOD preparations (which upon partial denaturation exhibit oxidant activity (21)) or alternatively may be due to differences in the cell isolates used, in the specific media components, or in the preparation of LDL.

The mechanism(s) of superoxide- and metal ion-dependent oxidation is not known with certainty and has been an area of intense investigation for many years. By analogy to previous work, multiple mechanisms of superoxide- and ceruloplasmin-dependent oxidation should be considered including: (i) the Fenton reaction in which Obardot 2 and H2O2 causes metal ion-dependent production of highly reactive OH·, (ii) recycling of the oxidation state of the oxidant copper by reduction by Obardot 2, (iii) Obardot 2-dependent release of copper from ceruloplasmin analogous to the release of Fe2+ from ferritin (52, 53), (iv) formation of a putative ``percupryl ion'', i.e., a Cu2+/Obardot 2 radical analogous to the proposed perferryl ion (54), or (v) Obardot 2-mediated oxidation of Cu2+ to the powerful oxidant Cu3+ (55). The first of these mechanisms is unlikely because our studies with catalase indicate that hydrogen peroxide is not required for LDL oxidation. Additional work will be necessary to determine if one of the remaining mechanisms is operative. The possible requirement for interaction of ceruloplasmin with receptors on vascular cells or with LDL also remain key unanswered issues.

According to one theory of atherosclerosis, oxidation of LDL within the wall of major arteries has a key and causative role in the onset and progression of the disease (6). According to our results, co-localization of Obardot 2, ceruloplasmin, and LDL in the same region of the vessel wall would be consistent with the oxidation of the latter. Studies in Watanabe hyperlipemic rabbits show that oxidized LDL is found in macrophage-rich early lesions and is associated with intimal and medial SMC, as well as the necrotic core, in advanced lesions (56). Recent data from several laboratories suggest that Obardot 2 is produced by the endothelium in hypercholesterolemic rabbit aorta (57) and by medial and adventitial SMC in normal rabbit aorta (58). Detectable levels of ceruloplasmin in human atherosclerotic lesions have been reported (59, 60). However, the structural integrity, localization, and source of ceruloplasmin in the vessel wall are not known. EC-mediated uptake from the plasma compartment is one possible source, as is synthesis and secretion by vascular cells. Consistent with the latter mechanism, Fleming et al. (61) have shown that cytokine-stimulated pulmonary macrophages in vitro express the ceruloplasmin gene and synthesize and secrete the protein. There are not any published reports showing production of ceruloplasmin by EC or SMC, and the presence of ceruloplasmin in vessel wall regions adjacent to these cell types has not been examined.

There is no direct evidence that ceruloplasmin expresses oxidant activity in vivo. However, according to a recent report comparing ``oxidation-related'' serum constituents with serum lipid oxidation levels by multivariate analysis, the strongest association was found for ceruloplasmin (62). Furthermore, plasma ceruloplasmin levels are elevated in patients with vascular diseases including abdominal aortic aneurysms, vasculitis, and peripheral arterial disease (63, 64). Although these correlations may be a noncausative result of an accompanying acute phase response, case-control studies also show serum ceruloplasmin is a risk factor for coronary heart disease (65, 66). The recent discovery of patients with mutations in the ceruloplasmin gene and consequent ``aceruloplasminemia'' (67, 68, 69) may provide insights into the role of ceruloplasmin in vascular disease onset and progression. However, severe complications including pathologic iron accumulation and diabetes may obfuscate any direct role of ceruloplasmin. Studies using transgenic animals lacking specific functional domains of ceruloplasmin, e.g., the putative ``oxidant activity domain,'' may be necessary to elucidate the role of the protein in lipid and lipoprotein oxidation processes in vivo.


FOOTNOTES

*   This work was supported by Grants HL29582 and HL52692 and by a Minority Supplement Award (to E. E.) from the National Heart Lung and Blood Institute, National Institutes of Health, by a grant-in-aid from the American Heart Association of Northeast Ohio, and by an Established Investigator Award of the American Heart Association. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed: Dept. of Cell Biology, Cleveland Clinic Research Inst., 9500 Euclid Ave., Cleveland, OH 44195. Tel.: 216-444-8053; Fax: 216-444-9404.
1   The abbreviations used are: LDL, low density lipoprotein; EC, endothelial cells; LPDS, lipoprotein-deficient serum; SMC, smooth muscle cells; SOD, superoxide dismutase; TBARS, thiobarbituric acid-reacting substances.

Acknowledgments

We gratefully acknowledge helpful discussions with Drs. Martha Cathcart, Guy Chisolm, Barsanjit Mazumder, and Gurunathan Murugesan and the expert technical assistance of Alan Prok.


REFERENCES

  1. Ylä-Herttuala, S. (1991) Ann. Med. 23, 561-567 [Medline] [Order article via Infotrieve]
  2. Henriksen, T., Mahoney, E. M., Steinberg, D. (1983) Arteriosclerosis 3, 149-159 [Abstract/Free Full Text]
  3. Quinn, M. T., Parthasarathy, S., Fong, L. G., Steinberg, D. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 2995-2998 [Abstract/Free Full Text]
  4. Navab, M., Imes, S. S., Hama, S. Y., Hough, G. P., Ross, L. A., Bork, R. W., Valente, A. J., Berliner, J. A., Drinkwater, D. C., Laks, H., Fogelman, A. M. (1991) J. Clin. Invest. 88, 2039-2046
  5. Berliner, J. A., Territo, M. C., Sevanian, A., Ramin, S., Kim, J. A., Bamshad, B., Esterson, M., Fogelman, A. M. (1990) J. Clin. Invest. 85, 1260-1266
  6. Chisolm, G. M., and Penn, M. S. (1995) in Atherosclerosis and Coronary Artery Disease (Fuster, V., Ross, R., and Topol, E., eds) Raven Press, Ltd., New York
  7. Autio, I., Jaakkola, O., Solakivi, T., Nikkari, T. (1990) FEBS Lett. 277, 247-249 [CrossRef][Medline] [Order article via Infotrieve]
  8. Murugesan, G., Chisolm, G. M., Fox, P. L. (1993) J. Cell Biol. 120, 1011-1019 [Abstract/Free Full Text]
  9. Ylä-Herttuala, S., Palinski, W., Rosenfeld, M. E., Parthasarathy, S., Carew, T. E., Butler, S., Witztum, J. L., Steinberg, D. (1989) J. Clin. Invest. 84, 1086-1095
  10. Hoff, H. F., O'Neil, J. (1991) Arterioscler. Thromb. 11, 1209-1222 [Abstract/Free Full Text]
  11. Morel, D. W., DiCorleto, P. E., Chisolm, G. M. (1984) Arteriosclerosis 4, 357-364 [Abstract/Free Full Text]
  12. Steinbrecher, U. P., Parthasarathy, S., Leake, D. S., Witztum, J. L., Steinberg, D. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 3883-3887 [Abstract/Free Full Text]
  13. Heinecke, J. W., Rosen, H., Chait, A. (1984) J. Clin. Invest. 74, 1890-1894
  14. Cathcart, M. K., Morel, D. W., Chisolm, G. M. (1985) J. Leukocyte Biol. 38, 341-350 [Abstract]
  15. Parthasarathy, S., Printz, D. J., Boyd, D., Joy, L., Steinberg, D. (1986) Arteriosclerosis 6, 505-510 [Abstract/Free Full Text]
  16. Hiramatsu, K., Rosen, H., Heinecke, J. W., Wolfbauer, G., Chait, A. (1987) Arteriosclerosis 7, 55-60 [Abstract]
  17. Heinecke, J. W., Rosen, H., Suzuki, L. A., Chait, A. (1987) J. Biol. Chem. 262, 10098-10103 [Abstract/Free Full Text]
  18. Steinbrecher, U. P. (1988) Biochim. Biophys. Acta 959, 20-30 [Medline] [Order article via Infotrieve]
  19. Cathcart, M. K., McNally, A. K., Morel, D. W., Chisolm, G. M. (1989) J. Immunol. 142, 1963-1969 [Abstract]
  20. Parthasarathy, S., Wieland, E., Steinberg, D. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 1046-1050 [Abstract/Free Full Text]
  21. Jessup, W., Simpson, J. A., Dean, R. T. (1993) Atherosclerosis 99, 107-120 [CrossRef][Medline] [Order article via Infotrieve]
  22. Halliwell, B., Gutteridge, J. M. C. (1990) Methods Enzymol. 186, 1-85 [CrossRef][Medline] [Order article via Infotrieve]
  23. Abdalla, D. S. P., Campa, A., Monteiro, H. P. (1992) Atherosclerosis 97, 149-159 [CrossRef][Medline] [Order article via Infotrieve]
  24. Balla, G., Jacob, H. S., Eaton, J. W., Belcher, J. D., Vercellotti, G. M. (1991) Arterioscler. Thromb. 11, 1700-1711 [Abstract/Free Full Text]
  25. Lamb, D. J., Leake, D. S. (1994) FEBS Lett. 352, 15-18 [CrossRef][Medline] [Order article via Infotrieve]
  26. Wieland, E., Parthasarathy, S., Steinberg, D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5929-5933 [Abstract/Free Full Text]
  27. Heinecke, J. W., Li, W., Francis, G. A., Goldstein, J. A. (1993) J. Clin. Invest. 91, 2866-2872
  28. Ehrenwald, E., Fox, P. L. (1994) Arch. Biochem. Biophys. 309, 392-395 [CrossRef][Medline] [Order article via Infotrieve]
  29. Ehrenwald, E., Chisolm, G. M., Fox, P. L. (1994) J. Clin. Invest. 93, 1493-1501
  30. Lamb, D. J., Leake, D. S. (1994) FEBS Lett. 338, 122-126 [CrossRef][Medline] [Order article via Infotrieve]
  31. Swain, J. A., Darley-Usmar, V., Gutteridge, J. M. C. (1994) FEBS Lett. 342, 49-52 [CrossRef][Medline] [Order article via Infotrieve]
  32. Rydén, L. (1984) Copper Proteins and Copper Enzymes (Lontie, R., eds) , Vol III, p. 37, CRC Press Inc., Boca Raton, FL
  33. Fox, P. L., Mukhopadhyay, C., Ehrenwald, E. (1995) Life Sci. 56, 1749-1758 [CrossRef][Medline] [Order article via Infotrieve]
  34. Messerschmidt, A., Huber, R. (1990) Eur. J. Biochem. 187, 341-352 [Medline] [Order article via Infotrieve]
  35. Sunderman, F. W., Nomoto, S. (1970) Clin. Chem. 16, 903-910 [Abstract]
  36. Fox, P. L., DiCorleto, P. E. (1984) J. Cell. Physiol. 121, 298-308 [CrossRef][Medline] [Order article via Infotrieve]
  37. Ross, R. (1971) J. Cell Biol. 50, 172-186 [Abstract/Free Full Text]
  38. Hessler, J. R., Morel, D. W., Lewis, L. J., Chisolm, G. M. (1983) Arteriosclerosis 3, 215-222 [Abstract/Free Full Text]
  39. Esterbauer, H., Striegl, G., Puhl, H., Rothender, M. (1989) Free Radical Res. Commun. 6, 67-75 [Medline] [Order article via Infotrieve]
  40. El-Saadani, M., Esterbauer, H., El-Sayed, M., Goher, M., Nassar, A. Y., Jürgens, G. (1989) J. Lipid Res. 30, 627-630 [Abstract]
  41. Nakamura, K., Handa, S. (1984) Anal. Biochem. 142, 406-410 [CrossRef][Medline] [Order article via Infotrieve]
  42. Heinecke, J. W., Baker, L., Rosen, H., Chait, A. (1986) J. Clin. Invest. 77, 757-761
  43. Heery, J. M., Kozak, M., Stafforini, D. M., Jones, D. A., Zimmerman, G. A., McIntyre, T. M., Prescott, S. M. (1995) J. Clin. Invest. 96, 2322-2330
  44. Kalant, N., McCormick, S. (1992) Biochim. Biophys. Acta 1128, 211-219 [Medline] [Order article via Infotrieve]
  45. Dabbagh, A. J., Frei, B. (1995) J. Clin. Invest. 96, 1958-1966
  46. Kelner, M. J., Bagnell, R., Welch, K. J. (1990) J. Biol. Chem. 265, 1306-1311 [Abstract/Free Full Text]
  47. Savenkova, M. I., Mueller, D. M., Heinecke, J. W. (1994) J. Biol. Chem. 269, 20394-20400 [Abstract/Free Full Text]
  48. Thomas, C. E. (1992) Biochim. Biophys. Acta 1128, 50-57 [Medline] [Order article via Infotrieve]
  49. Heinecke, J. W., Kawamura, M., Suzuki, L., Chait, A. (1993) J. Lipid Res. 34, 2051-2061 [Abstract]
  50. Parthasarathy, S. (1994) Modified Lipoproteins in the Pathogenesis of Atherosclerosis, Chapter 5, pp. 91-119, R. G. Landes, Austin, TX
  51. van Hinsbergh, V. W., Scheffer, M., Havekes, L., Kempen, H. J. (1986) Biochim. Biophys. Acta 878, 49-64 [Medline] [Order article via Infotrieve]
  52. Biemond, P., Van Eijk, H. G., Swaak, A. J., Koster, J. F. (1984) J. Clin. Invest. 73, 1576-1579
  53. Thomas, C. E., Morehouse, L. A., Aust, S. D. (1985) J. Biol. Chem. 260, 3275-3280 [Abstract/Free Full Text]
  54. Svingen, B. A., Buege, J. A., O'Neal, F. O., Aust, S. D. (1979) J. Biol. Chem. 254, 5892-5899 [Abstract/Free Full Text]
  55. Czapski, G., Goldstein, S., Meyerstein, D. (1988) Free Radical Res. Commun. 4, 231-236 [Medline] [Order article via Infotrieve]
  56. Rosenfeld, M. E., Palinski, W., Ylä-Herttuala, S., Butler, S., Witztum, J. L. (1990) Arteriosclerosis 10, 336-349 [Abstract/Free Full Text]
  57. Ohara, Y., Peterson, T. E., Harrison, D. G. (1993) J. Clin. Invest. 91, 2546-2551
  58. Pagano, P. J., Ito, Y., Tornheim, K., Gallop, P. M., Tauber, A. I., Cohen, R. A. (1995) Am. J. Physiol. 268, H2274-H2280
  59. Hollander, W., Colombo, M. A., Kirkpatrick, B., Paddock, J. (1979) Atherosclerosis 34, 391-405 [CrossRef][Medline] [Order article via Infotrieve]
  60. Swain, J., Gutteridge, J. M. C. (1995) FEBS Lett. 368, 513-515 [CrossRef][Medline] [Order article via Infotrieve]
  61. Fleming, R. E., Whitman, I. P., Gitlin, J. D. (1991) Am. J. Physiol. 260, L68-L74
  62. Craig, W. Y., Poulin, S. E., Palomaki, G. E., Neveux, L. M., Ritchie, R. F., Ledue, T. B. (1995) Arterioscler. Thromb. Vasc. Biol. 15, 733-739 [Abstract/Free Full Text]
  63. Powell, J. T., Muller, B. R., Greenhalgh, R. M. (1987) J. Cardiovasc. Surg. 28, 528-530 [Medline] [Order article via Infotrieve]
  64. Belch, J. J., Chopra, M., Hutchison, S., Lorimer, R., Sturrock, R. D., Forbes, C. D., Smith, W. E. (1989) Free Radical Biol. Med. 6, 375-378 [CrossRef][Medline] [Order article via Infotrieve]
  65. Reunanen, A., Knekt, P., Aaran, R. -K. (1992) Am. J. Epidemiol. 136, 1082-1090 [Abstract/Free Full Text]
  66. Mänttäri, M., Manninen, V., Huttunen, J. K., Palosuo, T., Ehnholm, C., Heinonen, O. P., Frick, M. H. (1994) Eur. Heart J. 15, 1599-1603 [Abstract/Free Full Text]
  67. Logan, J. I., Harveyson, K. B., Wisdom, G. B., Hughes, A. E., Archbold, G. P. R. (1994) Q. J. Med. 87, 663-670 [Abstract/Free Full Text]
  68. Harris, Z. L., Takahashi, Y., Miyajima, H., Serizawa, M., MacGillivray, R. T. A., Gitlin, J. D. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 2539-2543 [Abstract/Free Full Text]
  69. Yoshida, K., Furihata, K., Takeda, S., Nakamura, A., Yamamoto, K., Morita, H., Hiyamuta, S., Ikeda, S., Shimizu, N., Yanagisawa, N. (1995) Nat. Genet. 9, 267-272 [CrossRef][Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
N. Tapryal, C. Mukhopadhyay, D. Das, P. L. Fox, and C. K. Mukhopadhyay
Reactive Oxygen Species Regulate Ceruloplasmin by a Novel mRNA Decay Mechanism Involving Its 3'-Untranslated Region: IMPLICATIONS IN NEURODEGENERATIVE DISEASES
J. Biol. Chem., January 16, 2009; 284(3): 1873 - 1883.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
R. Stocker and J. F. Keaney Jr.
Role of Oxidative Modifications in Atherosclerosis
Physiol Rev, October 1, 2004; 84(4): 1381 - 1478.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. A. Voziyan, R. G. Khalifah, C. Thibaudeau, A. Yildiz, J. Jacob, A. S. Serianni, and B. G. Hudson
Modification of Proteins In Vitro by Physiological Levels of Glucose: PYRIDOXAMINE INHIBITS CONVERSION OF AMADORI INTERMEDIATE TO ADVANCED GLYCATION END-PRODUCTS THROUGH BINDING OF REDOX METAL IONS
J. Biol. Chem., November 21, 2003; 278(47): 46616 - 46624.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M.-L. Sentman, T. Brannstrom, S. Westerlund, M. O. Laukkanen, S. Yla-Herttuala, S. Basu, and S. L. Marklund
Extracellular Superoxide Dismutase Deficiency and Atherosclerosis in Mice
Arterioscler. Thromb. Vasc. Biol., September 1, 2001; 21(9): 1477 - 1482.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Exner, M. Hermann, R. Hofbauer, S. Kapiotis, P. Quehenberger, W. Speiser, I. Held, and B. M.K Gmeiner
Semicarbazide-sensitive amine oxidase catalyzes endothelial cell-mediated low density lipoprotein oxidation
Cardiovasc Res, June 1, 2001; 50(3): 583 - 588.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
B. Mazumder and P. L. Fox
Delayed Translational Silencing of Ceruloplasmin Transcript in Gamma Interferon-Activated U937 Monocytic Cells: Role of the 3' Untranslated Region
Mol. Cell. Biol., October 1, 1999; 19(10): 6898 - 6905.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. M. Chisolm III, S. L. Hazen, P. L. Fox, and M. K. Cathcart
The Oxidation of Lipoproteins by Monocytes-Macrophages. BIOCHEMICAL AND BIOLOGICAL MECHANISMS
J. Biol. Chem., September 10, 1999; 274(37): 25959 - 25962.
[Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
T. Kennedy, A. J. Ghio, W. Reed, J. Samet, J. Zagorski, J. Quay, J. Carter, L. Dailey, J. R. Hoidal, and R. B. Devlin
Copper-dependent Inflammation and Nuclear Factor-kappa B Activation by Particulate Air Pollution
Am. J. Respir. Cell Mol. Biol., September 1, 1998; 19(3): 366 - 378.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
N. Inoue, S. Kawashima, K.-I. Hirata, Y. Rikitake, S. Takeshita, W. Yamochi, H. Akita, and M. Yokoyama
Stretch force on vascular smooth muscle cells enhances oxidation of LDL via superoxide production
Am J Physiol Heart Circ Physiol, June 1, 1998; 274(6): H1928 - H1932.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. K. Mukhopadhyay, B. Mazumder, P. F. Lindley, and P. L. Fox
Identification of the prooxidant site of human ceruloplasmin: A model for oxidative damage by copper bound to protein surfaces
PNAS, October 14, 1997; 94(21): 11546 - 11551.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mukhopadhyay, C. K.
Right arrow Articles by Fox, P. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mukhopadhyay, C. K.
Right arrow Articles by Fox, P. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1996 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement